Seppic vs. Pharmactive: Saffron Extract Patent Dispute Ends in Mutual Dismissal After 904 Days

In a case that underscores the strategic complexity of nutraceutical patent litigation, Seppic, Inc.’s infringement dispute against Pharmactive Biotech Products, S.L.U. concluded on March 18, 2025, with a stipulated dismissal without prejudice — leaving no winner declared and both parties bearing their own legal costs after nearly two and a half years of litigation.

Filed on September 26, 2022, in the U.S. District Court for the District of New Jersey, the case centered on U.S. Patent No. US10933110B2, covering proprietary saffron extract technology, and the competing commercial products Affron® and Safr’Inside™. The dispute reflects intensifying patent infringement battles in the functional ingredients and botanical extract sector — a market where differentiation hinges on clinically validated, patent-protected compounds.

For patent attorneys, IP professionals, and R&D teams operating in the nutraceutical and botanical extract space, this case offers critical lessons in litigation strategy, declaratory judgment risk, and freedom-to-operate planning.

Case Overview

The Parties

The Patent at Issue

This case involved U.S. Patent No. US10933110B2 (Application No. US16/087585), covering saffron extract compositions and related technology. Saffron-derived compounds, particularly safranal and crocin-class molecules, have attracted significant IP activity due to their documented bioactive properties and growing consumer demand.

• • US10933110B2 — Saffron extract compositions and related technology.

The Accused Products

The litigation targeted Affron® and Safr’Inside™ — both standardized saffron extract products competing in overlapping market segments, including mood support, sleep quality, and antioxidant applications. The commercial significance of these products to each party’s ingredient business amplified the litigation stakes considerably.

Legal Representation

Plaintiff Seppic, Inc. retained a multi-firm legal team including Alston & Bird, McDermott, Will & Emery, LLP, and Walsh Pizzi O’Reilly Falanga, LLP, with attorneys Christine Clark, Liza M. Walsh, Jayita Guhaniyogi, Hector Daniel Ruiz, Selena Miriam Ellis, Wade G. Perrin, and William T. Walsh, Jr. leading the matter.

Defendant Pharmactive was represented by Sills Cummis & Gross PC, with Jeffrey J. Greenbaum and Katherine Marguerite Leid serving as counsel.

Litigation Timeline & Procedural History

The case was filed on September 26, 2022, in the U.S. District Court for the District of New Jersey — a jurisdiction frequently selected for complex pharmaceutical and specialty chemical patent disputes given its experienced bench and proximity to significant life sciences industry activity.

The litigation proceeded at the district court (first instance) level over a span of 904 days — approximately 2.5 years — before resolving through stipulated dismissal on March 18, 2025. This duration is consistent with contested patent infringement matters that involve technical complexity, claim construction proceedings, and potential validity challenges prior to any trial date.

The case was designated as a declaratory judgment action, indicating that at least one party sought judicial determination of patent rights — a procedural posture that frequently signals underlying licensing disputes or threatened enforcement actions that escalate to formal litigation. Specific motion practice, claim construction orders, or summary judgment rulings were not publicly detailed in the available case record.

📌 Suggested Visual: Litigation timeline infographic spanning September 2022 through March 2025, mapping key procedural phases against case duration benchmarks for NJ District Court patent matters.

The Verdict & Legal Analysis

Outcome

The case closed via stipulated dismissal without prejudice pursuant to Rule 41(a)(1)(A)(ii) of the Federal Rules of Civil Procedure. The parties — Seppic, Inc., Activ’Inside, and Pharmactive Biotech Products, S.L.U. — jointly agreed through counsel to dismiss all claims and counterclaims asserted by either side. Critically, each party bore its own costs, expenses, and attorneys’ fees.

No damages were awarded. No injunctive relief was granted. No judicial finding on patent validity or infringement was issued.

Verdict Cause Analysis

The action’s procedural basis was declaratory judgment, which suggests the litigation arose from or escalated alongside a patent enforcement or licensing dispute rather than a straightforward plaintiff-initiated infringement complaint. Declaratory judgment posture is commonly deployed when a potential defendant preemptively seeks court confirmation that its product does not infringe, or that the asserted patent is invalid — effectively forcing the patentee into litigation on the challenger’s chosen timeline and forum.

The involvement of Activ’Inside — a Seppic subsidiary and developer of Safr’Inside™ — as a co-party adds complexity, indicating that the IP ownership and commercial licensing structure across the Seppic-Activ’Inside relationship was likely central to the dispute’s scope.

The dismissal without prejudice is legally significant: it does not prevent either party from re-filing claims in the future. This is a materially different outcome from a dismissal with prejudice or a final judgment on the merits, which would carry preclusive effect.

Legal Significance

Because the case resolved through mutual stipulation before any substantive judicial ruling, US10933110B2 remains unlitigated on its merits. Its claims have not been construed by a court, its validity has not been adjudicated, and no infringement finding — positive or negative — exists on the public record. This creates an important consideration for third parties: the patent carries no weakening litigation history, but also no judicial endorsement of its scope.

The declaratory judgment framework used here reflects a broader trend in specialty ingredient patent disputes, where parties leverage litigation as a market-positioning and licensing-negotiation tool rather than pursuing adjudication to final judgment.

Strategic Takeaways

For Patent Holders: The absence of a merits ruling preserves optionality. Seppic retains the ability to assert US10933110B2 against other market participants or re-engage with Pharmactive if commercial circumstances change. However, the 904-day litigation duration and mutual cost-bearing arrangement signal that assertion strategy should be calibrated carefully against licensing alternatives.

For Accused Infringers: Pharmactive’s successful navigation to dismissal without any adverse finding demonstrates the value of a well-resourced defense posture in declaratory judgment contexts. Challenging validity through inter partes review (IPR) at the USPTO — a parallel track not evidenced in this record — remains an alternative defendants should evaluate early in saffron and botanical extract patent disputes.

For R&D Teams: When two competing standardized botanical extract products become the subject of patent litigation, product differentiation through documented manufacturing processes, standardization methodologies, and distinct biomarker profiles becomes not just a marketing advantage but a legal risk-mitigation strategy.

Industry & Competitive Implications

The Seppic v. Pharmactive dispute reflects the maturing competitive dynamics of the premium botanical extract ingredient market, where patent protection has become a primary tool for defending clinical investment and market position.

Saffron extract has emerged as one of the most commercially significant botanical categories globally, driven by clinical evidence supporting applications in mood, sleep, eye health, and cognition. As ingredient manufacturers compete for branded ingredient contracts with supplement companies, patent exclusivity directly impacts pricing power, partnership opportunities, and regulatory positioning.

The dismissal without prejudice leaves the competitive landscape between Affron® and Safr’Inside™ legally unsettled. Both products likely continue to compete in overlapping market segments, and the absence of a definitive court ruling means that future licensing discussions, third-party freedom-to-operate analyses, and competitive marketing claims will continue to operate in a zone of uncertainty regarding US10933110B2’s enforceability.

For companies formulating products with saffron extract ingredients, this case signals that supplier patent risk is a real procurement consideration requiring due diligence beyond label claims and clinical data review.

📌 Suggested Visual: Patent claim map of US10933110B2 highlighting key independent claims relevant to standardized saffron extract composition — sourced from USPTO Patent Center.

Future Watch

Monitor USPTO assignment records for US10933110B2 and related continuation applications; any IPR petition filings against this patent would materially affect the competitive landscape.

FAQ

What patent was involved in Seppic v. Pharmactive?

The dispute centered on U.S. Patent No. US10933110B2 (Application No. US16/087585), covering saffron extract technology.

Why was the case dismissed without prejudice?

The parties stipulated to mutual dismissal under FRCP Rule 41(a)(1)(A)(ii), with each side bearing its own costs. No court-issued finding on validity or infringement was rendered.

How does this affect saffron extract patent litigation going forward?

Because no merits ruling was issued, US10933110B2 remains legally untested. Parties operating in this space should conduct current freedom-to-operate analyses and monitor for re-filing or IPR activity.

For case docket access, visit PACER (Case No. 1:22-cv-05712, D.N.J.). Patent details available via USPTO Patent Center (US10933110B2).

Explore related cases in botanical extract and nutraceutical patent litigation, or subscribe to our patent litigation update series for emerging IP trends in the specialty ingredients sector.

📩 Contact our IP intelligence team for a full analysis of US10933110B2’s claim scope and freedom-to-operate implications for your saffron extract product portfolio.